Analyst Price Targets — LONA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 27, 2026 7:46 am | Kelsey Goodwin | Piper Sandler | $20.00 | $9.67 | StreetInsider | Piper Sandler Starts LeonaBio (LONA) at Overweight |
| February 18, 2026 9:40 pm | — | Mizuho Securities | $10.00 | $4.76 | TheFly | LeonaBio upgraded to Outperform from Neutral at Mizuho |
| September 19, 2025 11:02 am | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.83 | TheFly | Athira Pharma price target lowered to $4 from $5 at Mizuho |
| June 22, 2022 6:52 pm | Andrew Tsai | Jefferies | $3.00 | $2.85 | TheFly | Athira Pharma downgraded to Hold from Buy at Jefferies |
| April 21, 2022 8:46 am | — | Berenberg Bank | $33.00 | $11.63 | Benzinga | Berenberg Initiates Coverage On Athira Pharma with Buy Rating, Announces Price Target of $33 |
Latest News for LONA
BOTHELL, Wash., June 04, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that Javier San Martin, MD, Chief Medical Officer of LeonaBio, delivered a presentation at the 5th Annual ALS Drug Development Summit taking place June 2-4, 2026 in Boston,…
BOTHELL, Wash., May 27, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it will participate in the 5th Annual ALS Drug Development Summit, taking place June 2-4, 2026 in Boston, MA, and the BIO International Convention, taking place June 22-25, 2026 in…
Advancing Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator, a Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Expects to Complete Enrollment of Phase 3 Clinical Trial of Lasofoxifene in Treatment-Resistant ER-positive, HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline Data Anticipated in 2H 2027 On-track…
BOTHELL, Wash., May 07, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Fred Callori, J.D.
LeonaBio, Inc. (LONA) Discusses Modulation and Combination Strategies in ER-Positive Metastatic Breast Cancer and the Role of Lasofoxifene Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LONA.
U.S. House Trading
No House trades found for LONA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.